Compare Hims and Hers Health Inc (HIMS) vs Western Alliance Bancorporation (WAL) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with a Q2 2026 EPS estimate of $2.33. Strong profitability is evident with a net income margin of 25.63% and ROE of 13.47%, while valuation ratios like a P/E of 9.58 suggest potential undervaluation. Recent news highlights operational achievements, including being named Arizona's #1 bank by Forbes in June 2026.

The outlook for WAL is positive, supported by analyst consensus with 79% buy ratings and a $90.67 price target, implying ~12% upside. Investment opportunities include earnings growth and sector leadership, but risks involve negative operating cash flow in 2025 and high interest expenses of $1.83B that could pressure margins if rates rise.